The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
Combination Drug Therapy for the Management of Alzheimer’s Disease
Open accessAbstract
Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Even though the number of AD patients is rapidly growing, there is no effective treatment for this neurodegenerative disorder. At present, implementation of effective treatment approaches for AD is vital to meet clinical needs. In AD research, priorities concern the development of disease-modifying therapeutic agents to be used in the early phases of AD and the optimization of the symptomatic treatments predominantly dedicated to the more advanced AD stages. Until now, available therapeutic agents for AD treatment only provide symptomatic treatment. Since AD pathogenesis is multifactorial, use of a multimodal therapeutic intervention addressing several molecular targets of AD-related pathological processes seems to be the most practical approach to modify the course of AD progression. It has been demonstrated through numerous studies, that the clinical efficacy of combination therapy (CT) is higher than that of monotherapy. In case of AD, CT is more effective, mostly when started early, at slowing the rate of cognitive impairment. In this review, we have covered the major studies regarding CT to combat AD pathogenesis. Moreover, we have also highlighted the safety, tolerability, and efficacy of CT in the treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the combination use of appropriate cholinesterase inhibitors, such as donepezil (4) and galantamine (6), or the combination of cholinesterase inhibitors with other neurologic drugs, metal chelators, or antioxidants, may yield surprising effects in the management of cholinergic drugs in AD, including efficacy, tolerability, and safety.402,408”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [402]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Lipton, S. A., Choi, Y.-B., Pan, Z.-H., Lei, S. Z., Chen, H.-S. V., Sucher, N. J., Loscalzo, J., Singel, D. J., & Stamler, J. S. (1993) · Nature · doi:10.1038/364626a0 · Cited by 2,433
Nichols, E., Szoeke, C. E. I., Vollset, S. E., Abbasi, N., Abd-Allah, F., Abdela, J., Aichour, M. T. E., Akinyemi, R. O., Alahdab, F., Asgedom, S. W., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30403-4 · Cited by 2,412
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113
Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond
Lipton, S. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1958 · Cited by 909
Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial
Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Galvin, J. E., Emond, J., Jack, C. R., Weiner, M., et al. (2010) · JAMA · doi:10.1001/jama.2010.1510 · Cited by 764
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 521
“442 Levodopa was launched in 1970 to treat PD motor symptoms, and fi ve years later, the fi rst combined product of levodopa and carbidopa was approved 443 .”
BackgroundER stress and UPR in Alzheimer’s disease: mechanisms, pathogenesis, treatments
Ajoolabady, A., Lindholm, D., Ren, J., & Pratico, D. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05153-5 · Cited by 261
“Pathologically, AD displays the intracellular accumulation of phosphorylated tau protein and extracellular aggregation of amyloid β (Aβ) peptides in the brain, leading to a progressive albeit gradual impairment in cognitive function, ultimately, clinical dementia [16, 20].”
BackgroundKabir, M. T., Rahman, M. H., Shah, M., Jamiruddin, M. R., Basak, D., Al-Harrasi, A., Bhatia, S., Ashraf, G. M., Najda, A., El-kott, A. F., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112610 · Cited by 181
Self-citationMolecular Mechanisms of ER Stress and UPR in the Pathogenesis of Alzheimer’s Disease
Uddin, M. S., Tewari, D., Sharma, G., Kabir, M. T., Barreto, G. E., Bin-Jumah, M. N., Perveen, A., Abdel-Daim, M. M., & Ashraf, G. M. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01929-y · Cited by 164
Self-citationNeuroinflammation: A Potential Risk for Dementia
Ahmad, M. A., Kareem, O., Khushtar, M., Akbar, M., Haque, M. R., Iqubal, A., Haider, M. F., Pottoo, F. H., Abdulla, F. S., Al-Haidar, M. B., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020616 · Cited by 160
Uddin, M. S., Kabir, M. T., Rahman, M. S., Behl, T., Jeandet, P., Ashraf, G. M., Najda, A., Bin-Jumah, M. N., El-Seedi, H. R., & Abdel‐Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165858 · Cited by 147
“Currently, available therapies are mainly symptomatic and ineffective against the development of the disease [15].”
BackgroundSelf-citationDecoding microglial immunometabolism: a new frontier in Alzheimer's disease research
Jung, E. S., Choi, H., & Mook-Jung, I. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00825-0 · Cited by 124
“Given this complexity, the efficacy of monotherapies, such as Aβ-targeting antibody treatments, remains limited, highlighting the growing need for combination therapy strategies [9–11].”
Ginsenoside Rg1 in neurological diseases: From bench to bedside
Yang, S., Wang, J.-J., Cheng, P., Chen, L.-X., Hu, J., & Zhu, G. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-01022-1 · Cited by 128
“Reversibility Neuronal damage and reduction of brain region volume could be rescued or relieved [38, 190, 191] Hippocampal atrophy is irreversible, but neuronal damage could be reduced by drugs [192, 193] Ginsenoside Rg1 in neurological diseases SJ Yang et al.”
BackgroundWu, J., Yu, Y., Wan, Y., Xia, J., Xu, J., Zhang, L., Liu, D., Chen, L., Tang, F., Ao, H., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113207 · Cited by 128
Multi-Targets: An Unconventional Drug Development Strategy for Alzheimer’s Disease
Gong, C., Dai, C., Liu, F., & Iqbal, K. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.837649 · Cited by 128
Molecular Mechanisms of Metal Toxicity in the Pathogenesis of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Zaman, S., Begum, Y., Ashraf, G. M., Bin-Jumah, M. N., BUNGAU, S. G., Mousa, S. A., & Abdel‐Daim, M. M. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02096-w · Cited by 119
Self-citationUddin, M. S., Al Mamun, A., Kabir, M. T., Ashraf, G. M., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02116-9 · Cited by 86
“tacrine, while memantine is the only approved NMDAR antagonist [69, 70] as shown in Fig.”
BackgroundSelf-citationConifers Phytochemicals: A Valuable Forest with Therapeutic Potential
Bhardwaj, K., Sanches-Silva, A. T., Atanassova, M., Sharma, R., Nepovimová, E., Musílek, K., Sharma, R., Alghuthaymi, M. A., Dhanjal, D. S., Nicoletti, M., et al. (2021) · Molecules · doi:10.3390/molecules26103005 · Cited by 89
Haddad, H. W., Malone, G. W., Comardelle, N. J., Degueure, A. E., Kaye, A. M., & Kaye, A. D. (2022) · Health Psychology Research · doi:10.52965/001c.31925 · Cited by 93
Association of peripheral blood DNA methylation level with Alzheimer’s disease progression
Li, Q. S., Vasanthakumar, A., Davis, J. W., Idler, K. B., Nho, K. T., Waring, J. F., Saykin, A. J., & Initiative, A. D. N. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01179-2 · Cited by 74
“Although no curative treatments currently exist for AD, several disease-modifying therapies that aim to slow disease progression, especially during early stage, are under investigation [4, 5].”
BackgroundExploring the Role of PSEN Mutations in the Pathogenesis of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Setu, J. R., Ashraf, G. M., Bin-Jumah, M. N., & Abdel‐Daim, M. M. (2020) · Neurotoxicity Research · doi:10.1007/s12640-020-00232-x · Cited by 78
Self-citationUddin, M. S., Rahman, M. A., Kabir, M. T., Behl, T., Mathew, B., Perveen, A., Barreto, G. E., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · IUBMB Life · doi:10.1002/iub.2324 · Cited by 69
Self-citationRevisiting the role of brain and peripheral Aβ in the pathogenesis of Alzheimer's disease
Uddin, M. S., Kabir, M. T., Tewari, D., Mamun, A. A., Mathew, B., Aleya, L., Barreto, G. E., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116974 · Cited by 76
Self-citationBortolami, M., Rocco, D., Messore, A., Santo, R. D., Costi, R., Madia, V. N., Scipione, L., & Pandolfi, F. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1874344 · Cited by 73
Roy, J., Wong, K. Y., Aquili, L., Uddin, M. S., Heng, B. C., Tipoe, G. L., Wong, K.-H., Fung, M., & Lim, L. W. (2022) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2022.100986 · Cited by 65
Self-citationA review of the mechanisms underlying selected comorbidities in Alzheimer’s disease
Maciejewska, K., Czarnecka, K., & Szymański, P. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00293-5 · Cited by 64
Tau-targeting therapy in Alzheimer’s disease: Critical advances and future opportunities
Guo, Y., Li, S., Zeng, L.-H., & Tan, J. (2022) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2022.16 · Cited by 61
Löscher, W., & Klein, P. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107934 · Cited by 64
Kabir, M. T., Uddin, M. S., Jeandet, P., Emran, T. B., Mitra, S., Albadrani, G. M., Sayed, A. A., Abdel‐Daim, M. M., & Simal‐Gándara, J. (2021) · Marine Drugs · doi:10.3390/md19050251 · Cited by 71
Self-citationHajjo, R., Sabbah, D. A., Abusara, O. H., & Bawab, A. Q. A. (2022) · Diagnostics · doi:10.3390/diagnostics12122975 · Cited by 62
Lipid nanoparticle (LNP) mediated mRNA delivery in neurodegenerative diseases
Moosavi, S. G., Rahiman, N., Jaafari, M. R., & Arabi, L. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113641 · Cited by 60
Martins, M. M., Branco, P. S., & Ferreira, L. M. (2023) · ChemistrySelect · doi:10.1002/slct.202300461 · Cited by 52
Molecular Genetics of Early- and Late-Onset Alzheimer’s Disease
Uddin, M. S., Hasana, S., Hossain, M. F., Islam, M. S., Behl, T., Perveen, A., Hafeez, A., & Ashraf, G. M. (2020) · Current Gene Therapy · doi:10.2174/1566523220666201123112822 · Cited by 64
Self-citationAnti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer’s Disease
Amat-ur-Rasool, H., Ahmed, M., Hasnain, S., & Carter, W. G. (2021) · Brain Sciences · doi:10.3390/brainsci11020184 · Cited by 43
“The FDA approved concomitant use of memantine and ChEIs has primarily proved clinical efficacious and comparable to monotherapies, and for some studies provided additional benefit of reduced neurobehavioral symptoms [48].”
BackgroundTokgöz, S., & Claassen, J. A. H. R. (2021) · Cardiology and Therapy · doi:10.1007/s40119-020-00209-z · Cited by 42
“To date, pharmacological agents only provide symptomatic treatment by targeting, for example, the synaptic dysfunction, Ab accumulation and phosphorylation signalling pathways [15], and the efficiency can be increased by combining therapeutics [16].”
BackgroundRemya, C., Dileep, K. V., Reddy, E. K., Mantosh, K., Kesavan, L., Jacob, R. S., Sajith, A. M., Variyar, E. J., Anwar, S., Zhang, K. Y. J., et al. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.07.041 · Cited by 45
Liu, P., Zhang, T., Wu, Y., Chen, Q., Sun, T., & Jiang, C. (2024) · Advanced Materials · doi:10.1002/adma.202408729 · Cited by 46
Uddin, M. S., Mamun, A. A., Sumsuzzman, D. M., Ashraf, G. M., Perveen, A., BUNGAU, S. G., Mousa, S. A., El-Seedi, H. R., Bin-Jumah, M. N., & Abdel‐Daim, M. M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01097 · Cited by 40
Self-citationGuo, Q., Li, Y., Xu, S., Wang, P., Qian, K., Yang, P., Sheng, D., Wang, L., Cheng, Y., Meng, R., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.074 · Cited by 40
Gao, X., Li, S., Cong, C., Wang, Y., & Xu, L. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/2302680 · Cited by 50
“Improving cognitive deficits before the onset of AD can reduce disease severity, and consequently, clinicians often prescribe cholinesterase inhibitors or memantine to alleviate symptoms [13, 14].”
BackgroundPuranik, N., & Song, M. (2024) · Molecules · doi:10.3390/molecules29235744 · Cited by 54
“Still, these drugs could not change mechanisms that cause the disease at the same time [30,182].”
Stem Cell Therapy for Alzheimer’s Disease: A Scoping Review for 2017–2022
Duan, Y., Lyu, L., & Zhan, S. (2023) · Biomedicines · doi:10.3390/biomedicines11010120 · Cited by 41
“As the level of severity of AD increases, the lack of vitality of body cells also inhibits the effective transportation of drug molecules [6].”
BackgroundPiperidine: A Versatile Heterocyclic Ring for Developing Monoamine Oxidase Inhibitors
Jayan, J., Chandran, N., Thekkantavida, A. C., Abdelgawad, M. A., Ghoneim, M. M., Shaker, M. E., Uniyal, P., Benny, F., Zachariah, S. M., Kumar, S., et al. (2023) · ACS Omega · doi:10.1021/acsomega.3c05883 · Cited by 34
Self-citationArbo, B. D., Schimith, L. E., dos Santos, M. G., & Hort, M. A. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174800 · Cited by 34
Haddad, H. W., Malone, G. W., Comardelle, N. J., Degueure, A. E., Poliwoda, S., Kaye, R. J., Murnane, K. S., Kaye, A. M., & Kaye, A. D. (2022) · Health Psychology Research · doi:10.52965/001c.37023 · Cited by 43
Kiris, İ., Kukuła‐Koch, W., Karayel‐Basar, M., Gürel, B., Coşkun, J., & Baykal, A. T. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114111 · Cited by 35
Ng, S., Hornblass, A., Habibi, P., Ikramuddin, S., Chen, J. C., Feng, W., & Cai, D. (2025) · Stroke and vascular neurology · doi:10.1136/svn-2025-004048 · Cited by 28
“Future studies to evaluate the efficacy of combining pharmacological and non-pharmacological interventions in VaD prevention are needed.”
Advances in Drug Therapy for Alzheimer’s Disease
Zhu, C.-C., Fu, S., Chen, Y., Li, L., Mao, R., Wang, J., Liu, R., Liu, Y., & Wang, X. (2020) · Current Medical Science · doi:10.1007/s11596-020-2281-2 · Cited by 38
Evidence Linking Protein Misfolding to Quality Control in Progressive Neurodegenerative Diseases
Kabir, M. T., Uddin, M. S., Abdeen, A., Ashraf, G. M., Perveen, A., Hafeez, A., Bin-Jumah, M. N., & Abdel‐Daim, M. M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200618114924 · Cited by 29
Self-citationXue, T., Zhang, R., Wang, L., Li, X., & Gong, W. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220904 · Cited by 29
“The reported causative or risk factors for AD include the presence of mutations in genes encoding presenilin 1/2, amyloid precursor protein, family history, age, low education level, and so on [5].”
Exosomes in neurodegenerative diseases: Therapeutic potential and modification methods
Chen, H., Li, N., Cai, Y., Ma, C., Ye, Y., Shi, X., Guo, J., Han, Z., Liu, Y., & Wei, X. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00720 · Cited by 33
“However, existing clinical drugs for AD only alleviate specific symptoms and do not halt the progression of the disease (Kabir et al., 2020).”
Lekmine, S., Benslama, O., Tahraoui, H., Ola, M. S., Laouani, A., Kadi, K., Martín-García, A. I., & Ali, A. (2024) · Pharmaceuticals · doi:10.3390/ph17030348 · Cited by 27
Sugandhi, V. V., Gadhave, D. G., Ugale, A. R., Kulkarni, N. N., Nangare, S., Patil, H. P., Rath, S., Saxena, R., Lavate, A., Patel, A. T., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102775 · Cited by 35
“In line with these findings, the Alzheimer ’ s Association Research Roundtable 2018 strongly emphasized the urgent need for combination therapies, highlighting their potential for advancing treatment options (Kabir et al., 2020).”
Amat-ur-Rasool, H., Ahmed, M., Hasnain, S., Ahmed, A., & Carter, W. G. (2021) · Current Issues in Molecular Biology · doi:10.3390/cimb44010012 · Cited by 31
Gutti, G., Leifeld, J., Ramakrishna, K., Bajad, N. G., Ganeshpurkar, A., Kumar, A., Krishnamurthy, S., Klein-Schmidt, C., Tapken, D., Hollmann, M., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115670 · Cited by 27
Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review
Blumenfeld, A. M., Lipton, R. B., Silberstein, S. D., Tepper, S. J., Charleston, L. I., Landy, S. H., Kuruvilla, D. E., & Adams, A. M. (2023) · Neurology and Therapy · doi:10.1007/s40120-023-00529-x · Cited by 26
“Combination treatments are now widely used for an array of complex diseases, including cancer, infectious diseases, and neurodegenerative disorders [3, 129].”
BackgroundA Synergistic Combination of DHA, Luteolin, and Urolithin A Against Alzheimer’s Disease
Jayatunga, D. P. W., Hone, E., Fernando, W. M. A. D. B., Garg, M. L., Verdile, G., & Martins, R. N. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.780602 · Cited by 27
“Due to the toxicity associated with the use of currently available drugs and their limited therapeutic effectiveness, the purposed drugs for AD are being repositioned as combinations (Cummings et al., 2019; Kabir et al., 2020).”
BackgroundMastropasqua, L., Agnifili, L., Ferrante, C., Sacchi, M., Figus, M., Rossi, G. C. M., Brescia, L., Aloia, R., & Orlando, G. (2022) · Nutrients · doi:10.3390/nu14142963 · Cited by 27
“As observed in many forms of NDs, the mechanisms underlying the neuronal damage were often multifactorial [25,26].”
BackgroundA consolidated review on stem cell therapy for treatment and management of Alzheimer's disease
Ahmad, F., & Sachdeva, P. (2022) · Aging Medicine · doi:10.1002/agm2.12216 · Cited by 26
Hsieh, K., Plascencia‐Villa, G., Lin, K., Perry, G. L., Jiang, X., & Kim, Y. (2022) · iScience · doi:10.1016/j.isci.2022.105678 · Cited by 28
“AD is multifactorial and the use of multi-target therapeutic interventions addressing several molecular targets seems to be an alternative approach to modify the course of AD progression.(52) Different clinical studies demonstrate that combination therapy is more efficient than monotherapy, especially in mild-to-moder…”
BackgroundCáceres, C., Heusser, B., Garnham, A., & Moczko, E. (2023) · Cells · doi:10.3390/cells12232669 · Cited by 27
“For example, gene therapy approaches that involve the delivery of genes encoding cholinergic enzymes or receptors to the brain are being studied as potential treatments for AD.”
Grosso, C., Silva, A., Delerue-Matos, C. M., & Barroso, M. F. (2023) · Pharmaceuticals · doi:10.3390/ph16121721 · Cited by 26
“The benefits of combined therapy for AD were also highlighted by Kabir et al. [10].”
BackgroundHanda, M., Sanap, S. N., Bhatta, R. S., Patil, G. P., Palkhade, R., Singh, D. P., & Shukla, R. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00454 · Cited by 25
Niazi, S. K., Magoola, M., & Mariam, Z. (2024) · Pharmaceuticals · doi:10.3390/ph17060741 · Cited by 36
“…ff ering an optimal approach for AD patients. strategies to create hybrid molecules that can modulate multiple biological targets simultaneously [32,33] Table Consequently, researchers are increasingly focusing on multi-target-directed ligand strategies to create hybrid molecules that can modulate…”
BackgroundAlzheimer Combination Therapies: Overview and Scenarios
Cummings, J. L., Burstein, A. H., & Fillit, H. M. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100328 · Cited by 22
“Combination treatment might address amyloid beta protein (A ß ) _plus tau, tau plus inflammation, tau plus synaptic plasticity, tau plus neuroprotection or other combinations where each agent is expected to contribute to the pharmacodynamic response[13].”
Exploring the New Horizon of AdipoQ in Obesity-Related Alzheimer’s Dementia
Uddin, M. S., Rahman, M. M., Sufian, M. A., Jeandet, P., Ashraf, G. M., Bin-Jumah, M. N., Mousa, S. A., Abdel‐Daim, M. M., Akhtar, M. F., Saleem, A., et al. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2020.567678 · Cited by 24
Self-citationNovel melatonin-trientine conjugate as potential therapeutic agents for Alzheimer’s disease
Li, L., Fan, Y., Wu, W., Bai, C., Jia, M., Hu, J.-P., Gao, H., Wang, T., Zhong, M., Huang, X., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106100 · Cited by 24
Deciphering the Interacting Mechanisms of Circadian Disruption and Alzheimer’s Disease
Uddin, M. S., Sumsuzzman, D. M., Jeandet, P., Behl, T., Rauf, A., Amran, M. S., & Ashraf, G. M. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03325-x · Cited by 24
“Presently available AD drugs including cholinesterase inhibitors and N-methyl-d-aspartate receptor antagonists can only manage the symptoms [6, 7].”
Self-citationWei, Z., Yang, C., Feng, K., Guo, S., Huang, Z., Wang, Y., & Jian, C. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.11.078 · Cited by 18
Novel Pharmaceutical Approaches in Dementia
Tanaka, M., Török, N., & Vécsei, L. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_444-1 · Cited by 22
Wang, J., Liu, P., Huang, X., & Wu, X. (2020) · Annals of Palliative Medicine · doi:10.21037/apm-20-357 · Cited by 19
Molecular mechanisms of Alzheimer’s disease: From therapeutic targets to promising drugs
Alan, E., Kerry, Z., & Sevin, G. (2023) · Fundamental & Clinical Pharmacology · doi:10.1111/fcp.12861 · Cited by 17
“In addition, considering that ChEI alone may be insufficient to stop the progression of AD, combined hybrid molecules such as donepezil+clioquinol, rivastigmine+rasagiline, memantine+nitroglycerin (nitromemantine) have been examined as new multitargeted drug candidates.(139) Namzaric, which combines memantine and done…”
BackgroundPermanently Charged Cationic Lipids—Evolution from Excipients to Therapeutic Lipids
Pushpa Ragini, S., Banerjee, R., Drummond, C. J., & Conn, C. E. (2024) · Small Science · doi:10.1002/smsc.202300270 · Cited by 21
Non-pharmacological treatment of Alzheimer’s disease: an update
Wang, S., Xu, H., Liu, G., & Chen, L.-M. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1527242 · Cited by 25
“The drugs widely used in the clinical treatment of AD include acetylcholinesterase inhibitors and NMDA receptor antagonists, primarily for symptomatic treatment (Kabir et al., 2020).”
Неганова, М. Е., Aleksandrova, Y. R., Суслов, Е. В., Mozhaitsev, E. S., Munkuev, A. A., Tsypyshev, D. O., Chicheva, M. M., Rogachev, A. D., Sukocheva, O. A., Volcho, K. P., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111893 · Cited by 17
Coagulansin-A improves spatial memory in 5xFAD Tg mice by targeting Nrf-2/NF-κB and Bcl-2 pathway
Shal, B., Khan, A., Khan, A. U., Ullah, R., Naveed, M., Ali, G., Islam, S. U., Haq, I. U., Mirza, B., & Khan, S. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108860 · Cited by 17
Combination Therapy for the Treatment of Alzheimer’s Disease: Recent Progress and Future Prospects
Shirbhate, E., Patel, V. K., Tiwari, P., Kore, R., Veerasamy, R., Mishra, A., & Rajak, H. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220907114443 · Cited by 18
An overview about neurological diseases in India – A theranostics approach
Vellingiri, B. (2023) · Aging and Health Research · doi:10.1016/j.ahr.2023.100177 · Cited by 17
Guo, Y., Cai, C., Zhang, B., Tan, B., Tang, Q., Lei, Z., Qi, X., Chen, J., Zheng, X., Zi, D., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00146-7 · Cited by 18
Proposed Mechanisms of Cell Therapy for Alzheimer’s Disease
Belousova, E., Salikhova, D. I., Maksimov, Y., Nebogatikov, V. O., Sudina, A. K., Goldshtein, D. V., & Ustyugov, A. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212378 · Cited by 19
“This lack of stimulation can lead to reduced cell viability, which in turn inhibits drug transport [5].”
Mathew, B. (2020) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207323999200728122627 · Cited by 15
Self-citationBiswas, A., Verma, S. K., Kumar, S., Mishra, T., Kumar, M., Choudhury, A. D., Agrawal, S., Sanap, S. N., Bisen, A. C., Mishra, A., et al. (2023) · Current Drug Metabolism · doi:10.2174/1389200224666230817101950 · Cited by 16
Koshatwar, M., Acharya, S., Prasad, R., Lohakare, T., Wanjari, M. B., & Taksande, A. B. (2023) · Cureus · doi:10.7759/cureus.44763 · Cited by 20
“By targeting multiple pathological processes simultaneously, combination therapies have the potential to exert synergistic effects and provide a more comprehensive approach to disease management [92].”
Recent Advancements in the Treatment of Alzheimer’s Disease: A Multitarget-directed Ligand Approach
Kumar, S., Mahajan, A. T., Ambatwar, R., & Khatik, G. L. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673264076230921065945 · Cited by 18
Hou, X., Jiang, H., Liu, T., Yan, J., Zhang, F., Zhang, X., Zhao, J., Mu, X., & Jiang, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114455 · Cited by 19
Jiang, F., Dong, Q., Wu, S., Liu, X., Dayimu, A., Liu, Y., Ji, H. L., Wang, L., Liu, T., Li, N., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03748-7 · Cited by 23
Knowledge graphs for enhancing transparency in health data ecosystems1
Aisopos, F., Jozashoori, S., Niazmand, E., Purohit, D., Rivas, A., Sakor, A., Iglesias, E., Vogiatzis, D., Menasalvas, E., Rodríguez‐González, A., et al. (2023) · Semantic Web · doi:10.3233/sw-223294 · Cited by 24
“They include treatments for COVID-19, Alzheimer, and Hypertension collected from scientific literature [2,24,30]; also, drugs for frequent comorbidities are part of these treatments.”
BackgroundMatos, M. J. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0119 · Cited by 16
Jiang, X., Liu, C., Zou, M., Xie, H., Lin, T., Lyu, W., Xu, J., Li, Y., Feng, F., Sun, H., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113663 · Cited by 13
Liu, Y., Chang, D., & Zhou, X. (2023) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2023/2558415 · Cited by 17
“, that has been shown to have potent antioxidant and antineuroinfammatory properties [17, 18].”
BackgroundThe Potential Effect of Insulin on AChE and Its Interactions with Rivastigmine In Vitro
Jamshidnejad-Tosaramandani, T., Kashanian, S., Babaei, M., Al-Sabri, M. H., & Schiöth, H. B. (2021) · Pharmaceuticals · doi:10.3390/ph14111136 · Cited by 12
Nguyen, H. D. (2022) · Neurotoxicity Research · doi:10.1007/s12640-022-00591-7 · Cited by 13
“Recently, the therapeutic medications available for the management of cognitive decline have only been symptomatic (Kabir et al. 2020).”
BackgroundInfluentialPerspectives on Alzheimer’s Disease Treatment Based on Counteracting Oxidative Stress
Bilski, R., Dąbkowski, S., Kozieł, I., Kozicki, M., Małachowska, A., Przygocki, M., & Tyska, O. (2025) · Biomolecules · doi:10.3390/biom15091345 · Cited by 13
Ahmad, F., Singh, G., Soni, H., & Tandon, S. (2022) · Aging Medicine · doi:10.1002/agm2.12232 · Cited by 11
Rathee, S., Sen, D., Pandey, V., & Jain, S. (2024) · Current Drug Targets · doi:10.2174/0113894501320096240627071400 · Cited by 16
Mitra, A., Roy, R., & Paul, S. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c04798 · Cited by 12
NMDA Inhibitors: A Potential Contrivance to Assist in Management of Alzheimer’s Disease
Painuli, S., Semwal, P., Zam, W., Taheri, Y., Ezzat, S. M., Zuo, P., Li, L., Kumar, D., Sharifi‐Rad, J., & Martins, N. A. (2022) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207325666220428112541 · Cited by 12
Brinza, I., Boiangiu, R. Ş., Honceriu, I., Abd-Alkhalek, A. M., Osman, S. M., Eldahshan, O. A., Todirașcu-Ciornea, E., Dumitru, G., & Hriţcu, L. (2025) · Biomolecules · doi:10.3390/biom15010138 · Cited by 11
“…inhibitors, particularly cholinesterase inhibitors (ChEIs), like donepezil, rivastigmine, and galantamine, are Food and Drug Administration (FDA) approved and effective for mild to moderate AD, working by inhibiting the break-down of acetylcholine [5,6], which is crucial for cognitive function.”
Co-Encapsulation of Multiple Antineoplastic Agents in Liposomes by Exploring Microfluidics
Asghar, S., Iliescu, R., Stiufiuc, R. I., & Drăgoi, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083820 · Cited by 10
“…is crucial for the treatment of cancer [2,3], heart diseases [4,5], metabolic disorders [6,7], renal malfunctions [8], neurological diseases [9,10], inflammatory diseases [11,12], and fatal infections like malaria [13], acquired immunodeficiency syndrome (AIDS) [14,15], tuberculosis…”
Maciejewska, K., Czarnecka, K., Kręcisz, P., Niedziałek, D., Wieczorek, G., Skibiński, R., & Szymański, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115876 · Cited by 12
“The priority of Alzheimer’s disease research is to develop a disease-modifying treatment that can be used in the early stage of AD, unlike currently used drugs that provide only symptomatic relief [19,23].”
BackgroundMethodGuo, J., Xu, A., Cheng, M., Wan, Y., Wang, R., Fang, Y., Jin, Y., Xie, S., & Liu, J. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s354879 · Cited by 9
Targeting PERK and GRP78 in colorectal cancer: Genetic insights and novel therapeutic approaches
Mafi, S., Dehghani, M., Khalvati, B., Abidi, H., Ghorbani, M., Jalali, P., Whichelo, R., Salehi, Z., Markowska, A., Reyes, A., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176899 · Cited by 10
Tan, H.-Y., Wan, C., Wu, G.-L., Qiao, L., Cai, Y.-F., Wang, Q., & Zhang, S. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116580 · Cited by 10
Donepezil-based combination therapy for Alzheimer’s disease and related neuropathies
Ekundayo, B. E., Obafemi, T. O., Adewale, O. B., & Oyinloye, B. E. (2023) · Comparative Clinical Pathology · doi:10.1007/s00580-023-03487-w · Cited by 8
“It provides the most efficient option to begin combination therapy (CT) in AD patients by combining two effective therapeutic medicines (donepezil and memantine) in a fixed-dose combo package (Kabir et al. 2020; Pardo-Moreno et al. 2022).”
Background
Metadata
- Authors
- Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M.
- Affiliations
- BRAC University (BD)
- Southeast University (BD)
- Centre National de la Recherche Scientifique (FR)
- King Abdulaziz University (SA)
- Division of Drug Design and Medicinal Chemistry Research Lab, Department of Pharmaceutical Chemistry, Ahalia School of Pharmacy, Palakkad 678557, India
- Princess Nourah bint Abdulrahman University (SA)
- Department of Zoology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia
- Corresponding author
- Uddin, Md. Sahab
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-05-05
- Volume
- 21
- Issue
- 9
- Pages
- 3272
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7246721
- OpenAlex
- W3022707404
- Cited by
- 217
- References
- 135
- Citations by year
- 2026: 26 · 2025: 43 · 2024: 34 · 2023: 30 · 2022: 40 · 2021: 27 · 2020: 17
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- HAL (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Griffith Research Online (submittedVersion, cc-by)
- Funders
- Princess Nourah Bint Abdulrahman University
- Deanship of Scientific Research, Princess Nourah Bint Abdulrahman University
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, combination therapy, multimodal therapy, disease-modifying therapy, symptomatic treatment, early intervention, cognitive impairment, drug safety and tolerability, drug efficacy
- MeSH terms
- Alzheimer Disease, Animals, Cholinesterase Inhibitors, Clinical Trials as Topic, Disease Susceptibility, Drug Therapy, Combination, Galantamine, Humans, Memantine, Dopamine Agents, Biomarkers, Disease Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.